Amicus Therapeutics, Inc. Earnings

Amicus Therapeutics, Inc.’s revenue jumped 36.73% since last year same period to $141.52Mn in the Q3 2024. On a quarterly growth basis, Amicus Therapeutics, Inc. has generated 11.72% jump in its revenue since last 3-months.

Amicus Therapeutics, Inc.’s net profit jumped 68.81% since last year same period to $-6.73Mn in the Q3 2024. On a quarterly growth basis, Amicus Therapeutics, Inc. has generated 57.13% jump in its net profits since last 3-months.

Amicus Therapeutics, Inc.’s net profit margin jumped 77.19% since last year same period to -4.75% in the Q3 2024. On a quarterly growth basis, Amicus Therapeutics, Inc. has generated 61.63% jump in its net profit margins since last 3-months.

Amicus Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.07.

Amicus Therapeutics, Inc.’s earning per share (EPS) jumped 71.43% since last year same period to -0.02 in the Q3 2024. This indicates that the Amicus Therapeutics, Inc. has generated 71.43% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Amicus Therapeutics, Inc.’s return on assets (ROA) stands at 0.01.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Amicus Therapeutics, Inc.’s return on equity (ROE) stands at -0.67.